<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098067</url>
  </required_header>
  <id_info>
    <org_study_id>1763191-1</org_study_id>
    <nct_id>NCT05098067</nct_id>
  </id_info>
  <brief_title>Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy</brief_title>
  <official_title>Trial of Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy: A Pilot Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Women and Infants Hospital of Rhode Island</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between fifty and eighty percent of pregnant women experience nausea and vomiting in&#xD;
      pregnancy making it one of the most common medical complications of pregnancy. Hyperemesis&#xD;
      gravidarum is an extreme form of nausea and vomiting of pregnancy and results in evidence of&#xD;
      acute starvation (i.e. large ketonuria), and weight loss (&gt;5% of a woman's pre-pregnancy&#xD;
      weight). Hyperemesis gravidarum is also surprisingly common. In fact, it is the second&#xD;
      leading cause of preterm hospitalization during pregnancy, second only preterm labor.&#xD;
      Hospitalization is often required because hyperemesis is frequently refractory to common&#xD;
      anti-nausea medications. However, capsaicin cream, a potent TRPV1 agonist, commonly used to&#xD;
      relieve muscular and neuropathic pain, may be able to reduce the symptoms of nausea and&#xD;
      emesis in patients with nausea and vomiting of pregnancy. Smaller studies have demonstrated&#xD;
      capsaicin to be both safe and effective when used to treat intraoperative nausea during&#xD;
      cesarean delivery. To begin to address whether capsaicin cream could be used to reduce&#xD;
      preterm admissions and shorten emergency room visits for hyperemesis, this study will&#xD;
      randomize women presenting to the emergency room for nausea and vomiting to treatment with&#xD;
      capsaicin cream as an adjunctive medication or routine care. The project will investigate the&#xD;
      impact of capsaicin cream on hospital length of stay as well as representation for additional&#xD;
      treatment. If effective, capsaicin cream has the potential not only to reduce emergency room&#xD;
      visits, hospital admissions and overall health care costs, but also to drastically improve&#xD;
      patient quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to symptom control</measure>
    <time_frame>180 minutes</time_frame>
    <description>Time to perceived symptom control as measured by a validated scale used to measure patient's perception of the severity of nausea and vomiting symptoms (i.e. VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of antiemetics needed for symptom control</measure>
    <time_frame>180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of emergency department stay</measure>
    <time_frame>180 minutes</time_frame>
    <description>Time to discharge from the emergency department</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperemesis Gravidarum</condition>
  <condition>Nausea Gravidarum</condition>
  <condition>Vomiting of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of 0.075% capsaicin cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS)11,12. The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of placebo cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS). The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin Topical Cream</intervention_name>
    <description>5g 0.075% applied once</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>10mg IV once</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>8mg IV once if needed</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactated Ringers, Intravenous</intervention_name>
    <description>1000cc once</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women in the first trimester (0-14 weeks gestation)&#xD;
&#xD;
          -  Presenting to the emergency room at Women &amp; Infants Hospital in Rhode Island with a&#xD;
             chief complaint of nausea and vomiting&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Have not taken an anti-emetic such as Reglan or Zofran within the 6 hours prior to&#xD;
             presentation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to Reglan, capsaicin or Zofran&#xD;
&#xD;
          -  Another identifiable source for nausea and vomiting (i.e. gastritis, COVID, diabetic&#xD;
             ketoacidosis)&#xD;
&#xD;
          -  Molar pregnancies,&#xD;
&#xD;
          -  Patients with a history of gastroparesis&#xD;
&#xD;
          -  Patients with a history of preexisting diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women and Infants Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Murphy, MD</last_name>
    <phone>210-722-2589</phone>
    <email>lmmurphy@wihri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maureen Hamel, MD</last_name>
    <phone>508-479-9190</phone>
    <email>mhamel@kentri.org</email>
  </overall_contact_backup>
  <link>
    <url>https://doi.org/10.1111/j.1553-2712.2009.00581.x</url>
    <description>11. Meek, R., Kelly, A.-M. and Hu, X.F. (2009), Use of the Visual Analog Scale to Rate and Monitor Severity of Nausea in the Emergency Department. Academic Emergency Medicine, 16: 1304-1310.</description>
  </link>
  <reference>
    <citation>Bleehen SS. Pigmented basal cell epithelioma. Light and electron microscopic studies on tumours and cell cultures. Br J Dermatol. 1975 Oct;93(4):361-70.</citation>
    <PMID>1201188</PMID>
  </reference>
  <reference>
    <citation>Piwko C, Koren G, Babashov V, Vicente C, Einarson TR. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013;20(2):e149-60. Epub 2013 Jul 10.</citation>
    <PMID>23913638</PMID>
  </reference>
  <reference>
    <citation>Gazmararian JA, Petersen R, Jamieson DJ, Schild L, Adams MM, Deshpande AD, Franks AL. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol. 2002 Jul;100(1):94-100.</citation>
    <PMID>12100809</PMID>
  </reference>
  <reference>
    <citation>Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol (Phila). 2018 Jan;56(1):15-24. doi: 10.1080/15563650.2017.1349910. Epub 2017 Jul 21.</citation>
    <PMID>28730896</PMID>
  </reference>
  <reference>
    <citation>Dean DJ, Sabagha N, Rose K, Weiss A, France J, Asmar T, Rammal JA, Beyer M, Bussa R, Ross J, Chaudhry K, Smoot T, Wilson K, Miller J. A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome. Acad Emerg Med. 2020 Nov;27(11):1166-1172. doi: 10.1111/acem.14062. Epub 2020 Jul 20.</citation>
    <PMID>32569429</PMID>
  </reference>
  <reference>
    <citation>Yuan LJ, Qin Y, Wang L, Zeng Y, Chang H, Wang J, Wang B, Wan J, Chen SH, Zhang QY, Zhu JD, Zhou Y, Mi MT. Capsaicin-containing chili improved postprandial hyperglycemia, hyperinsulinemia, and fasting lipid disorders in women with gestational diabetes mellitus and lowered the incidence of large-for-gestational-age newborns. Clin Nutr. 2016 Apr;35(2):388-393. doi: 10.1016/j.clnu.2015.02.011. Epub 2015 Mar 2.</citation>
    <PMID>25771490</PMID>
  </reference>
  <reference>
    <citation>Yosipovitch G, Mengesha Y, Facliaru D, David M. Topical capsaicin for the treatment of acute lipodermatosclerosis and lobular panniculitis. J Dermatolog Treat. 2005 Aug;16(3):178-80.</citation>
    <PMID>16096187</PMID>
  </reference>
  <reference>
    <citation>Boogaerts JG, Vanacker E, Seidel L, Albert A, Bardiau FM. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand. 2000 Apr;44(4):470-4.</citation>
    <PMID>10757584</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>capsaicin</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>pregnancy</keyword>
  <keyword>hyperemesis gravidarum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperemesis Gravidarum</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

